Extracellular vesicle scores largely remained stable on placebo, whereas KP405 was associated with statistically significant but variable within-subject shifts in insulin signaling, neuroprotection, ...
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Phase 3 randomized-withdrawal data in pediatrics indicated relapse in 41.9% continuing ecopipam versus 68.1% on placebo, a 53% relative relapse-risk reduction (HR, 0.50; P = .008). New analyses from ...
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
Treatment initiation before 90 days correlated with markedly higher independent walking (73.2% vs 36.7%) and fewer ...
The investigators set out to indirectly compare nipocalimab's safety, specifically any adverse event (AE) and any serious ...
The chairman of the Neurology Service Line at Baptist Health in Kentucky discusses PREVAIL findings on clinical deterioration, rescue therapy use, and hospitalization with gefurulimab in generalized ...
A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this ...
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results